中国药房2009，Vol.20Issue(29)：2284-2286,3.
瑞舒伐他汀10 mg·d~(-1)对国人调脂作用有效性和安全性的Meta分析
Lipid- regulatory Efficacy and Safety of Rosuvastatin (10 mg·d~(-1)) for Chinese Population: A Metaanalysis
郑雅婷 1周立岩 2刘松岭3
作者信息
- 1. 青岛市市立医院,青岛市,266011
- 2. 青岛市第八人民医院,青岛市,266100
- 3. 青岛市肿瘤医院,青岛市,266042
- 折叠
摘要
Abstract
OBJECTIVE: To evaluate the lipid - regulatory efficacy and safety of rosuvastatin (10 mg·d ~(-1)) for Chinese population. METHODS: The pertinent literature comparing the serum blood lipid level before and after treatment with rosuvastatin (10 mg·d~(-1)) between 2001 and 2008 were collected by retrieving Wanfang database, CNKI, Weipu electronic periodicals; and the data were given a meta - analysis using RevMan 4.2 software, meanwhile the safety of rosuvastatin was e-valuated. RESULTS: A total of 346 patients were enrolled in 5 trials. After treatment with rosuvastatin (10 mg·d ~(-1)), the low density lipoproteincholesterol(LDL-C) was lowered by 1.71 mmol·L ~(-1) on average; the total cholesterol (TC) was lowered by 1.98 mmol·L ~(-1) on average; high density lipoprotein cholesterol(HDL-C) was increased by 0.17 mmol·L ~(-1) on average; and the level of triglyeride was lowered by 0.79 mmol·L~(-1) on average. A total of 54 adverse events were reported, and the adverse drug reactions manifested chiefly as upper respiratory infection, mild notalgia, debilitation and gastrointestinal upset. No severe side effects were reported. CONCLUSION: It has been confirmed by domestic clinical trials that rosuvastatin (10 mg · d ~(-1)) is safe and effective for Chinese population.关键词
瑞舒伐他汀/Meta分析/调脂作用Key words
Rosuvastatin/ Meta-analysis/ Lipid - regulating efficacy分类
医药卫生引用本文复制引用
郑雅婷,周立岩,刘松岭..瑞舒伐他汀10 mg·d~(-1)对国人调脂作用有效性和安全性的Meta分析[J].中国药房,2009,20(29):2284-2286,3.
